To compare the efficacy and side effects of mirabegron and doxazosin in alleviating ureteral stent symptoms, with a specific focus on sexual dysfunction as a symptom.
Key Findings:
Both mirabegron and doxazosin were effective in reducing ureteral stent-related symptoms.
Mirabegron showed a potential advantage in alleviating sexual dysfunction compared to doxazosin.
Adverse effects were monitored, with both medications demonstrating a favorable safety profile.
Interpretation:
The study suggests that mirabegron may be a viable alternative to doxazosin for managing ureteral stent-related symptoms, particularly regarding sexual dysfunction.
Limitations:
Single-center study may limit generalizability.
Short follow-up duration post-stent removal may affect the reliability of long-term outcomes.
Conclusion:
Mirabegron appears to be an effective option for managing ureteral stent-related symptoms, particularly benefits for sexual dysfunction, warranting further investigation to validate these findings.
